US Patent 6924264 Modified exendins and exendin agonists
Patent 6924264 was granted and assigned to Amylin Pharmaceuticals on August, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 24 Jul, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
0
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 23 Oct, 2023
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+511 characters)
Article
Patent abstract
Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analogs, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Andrew A. Young0
Kathryn S. Prickett0
Date of Patent
August 2, 2005
0Patent Application Number
095612260
Date Filed
April 28, 2000
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6924264 Modified exendins and exendin agonists
Find more entities like US Patent 6924264 Modified exendins and exendin agonists
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.